1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD) and type 2 diabetes mellitus (T2DM) are two common and frequently occurring diseases of the elderly. Alzheimer\'s disease is characterized by neurodegenerative disorders, such as progressive memory loss, decline in language skills and cognitive dysfunction[@bib1]. About 46.8 million people worldwide are currently suffering from AD and one out of three dead seniors has been diagnosed with AD[@bib2]. Type 2 diabetes mellitus is a polygenic disease of metabolic disorder characterized by hyperglycemia, insulin resistance, and loss of *β*-cell function[@bib3], which is expected to affect about 370 million people worldwide by 2030[@bib4]. Recent clinical studies demonstrated that some pathological processes of AD and T2DM are linked to each other[@bib5], [@bib6], [@bib7]. The neuron damage in the brain of AD patients may be caused by hyperglycemia. A great number of patients with T2DM suffer a significant decline in cognitive function, and about 70% of them eventually develop to AD patients. Furthermore, patients with T2DM have a 1.5---2.5 times higher risk of AD than the general population.

Although the pathological links between AD and T2DM are still unclear, the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein kinase (PKG) signaling pathway has been identified to be important in the process of both AD and T2DM. For the AD patients, the NO/cGMP/PKG pathway is involved in the signal transduction and synaptic plasticity in the brain, which can activate the transcription factor cyclic adenosine monophosphate response element-binding protein (CREB) to enhance synaptic plasticity, neuronal growth, and then increase the activities of neurotrophic factors including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), *etc*.[@bib8]. In diabetes, the phosphorylation of vasodilator stimulated phosphoprotein (VASP), which plays a key role in the inhibition of platelet activation, can be induced by the activation of NO/cGMP/PKG pathway, resulting in the increased concentration of intracellular Ca^2+^ and attenuating vascular inflammation and insulin resistance[@bib9].

Phosphodiesterases (PDEs) are one super enzyme families in charge of hydrolyzing cAMP and cGMP. Among the 11 subfamilies of PDEs, PDE5, PDE6, and PDE9 specially hydrolyze cGMP, the inhibition of which can increase the level of cGMP and active the NO/cGMP/PKG signaling pathway efficiently[@bib10]. Numerous preclinical and clinical studies were performed to investigate the effect and underlying mechanisms of PDE5 and PDE9 inhibition for the treatment of AD or T2DM (The PDE6 enzyme is difficult to be obtained and no PDE6 inhibitor has been reported yet), demonstrating that PDEs worked as potential targets for AD or T2DM[@bib11], [@bib12].

Compared with PDE5 and other PDEs families, PDE9 has the highest affinity of cGMP, indicating that the inhibition of PDE9 might have better results than others to increase the level of cGMP[@bib13]. Several PDE9 inhibitors were patented for the potential treatment of AD or T2DM[@bib14], [@bib15], [@bib16]. For example, PDE9 inhibitor **3r** reported by our group can inhibit the mRNA expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G-6-Pase), working as a hypoglycemic agent potentially[@bib17]. PDE9 inhibitor BAY 73-6691 can enhance the ability of acquisition, consolidation, and retention of long-term memory (LTP), improving scopolamine-induced passive avoidance deficit and MK-801-induced short-term memory deficits in the social and object recognition tasks of rodents[@bib18]. Furthermore, PDE9 inhibitors PF-04447943 and BI-409306 have already been completed several Phase II clinical trials of AD currently[@bib19]. Despite of the unique advantages of PDE9 inhibitors and good therapeutic effects obtained in preclinical and clinical studies, researches on PDE9 inhibitors are relatively limited compared with other PDE families, such as PDE5 and PDE4, which have already have several marketed drugs. In order to accelerate the application of PDE9 inhibitors, discovery of novel and effective PDE9 inhibitors is in high demand.

Rosiglitazone is a peroxisome proliferator-activated receptor-*γ* (PPAR*γ*) agonist approved for the treatment of T2DM. It can increase insulin sensitivity, leading to the channeling of fatty acids into adipose tissue and reducing their concentration in the plasma, and thus alleviating insulin resistance and improving plasma glucose levels effectively[@bib20], [@bib21]. Recent studies demonstrated that rosiglitazone reduced A*β*-induced oxidative stress, toxicity and the tau phosphorylation, exerting neuroprotective and anti-inflammatory effects[@bib22]. Currently, rosiglitazone is under a Phase III clinical trial in AD patients.

In order to discover novel PDE9 inhibitors starting from a previously studied hit **C33**[@bib23] (IC~50~ = 16 nmol/L, [Fig. 1](#f0005){ref-type="fig"}), a series of pyrazolo\[3,4-*d*\]pyrimidinone derivatives containing the pharmacophore of rosiglitazone, were designed, synthesized, and bioassayed in this study. As a result, four of them have the IC~50~ less than 5 nmol/L. Compound **11a**, has the best IC~50~ of 1.1 nmol/L against PDE9, which is significantly better than the reference compounds PF-04447943 (IC~50~ = 8 nmol/L)[@bib19] and BAY 73--6691 (IC~50~ = 48 nmol/L). The putative binding patterns and binding free energy analysis of these compounds with PDE9 by molecular modelling approaches may explain the structure---activity relationships and provide evidence for further structural modifications.Figure 1Structure-based design of novel PDE9 inhibitors.Fig. 1

2. Result and discussion {#s0010}
========================

2.1. Structure-based design of novel PDE9 inhibitors {#s0015}
----------------------------------------------------

Gln453 and Phe456 are two conservative amino acid residues in the binding site pocket of PDE9, the interactions with which are regarded to be important for the high-affinity PDE9 inhibitors. Most current PDE9 inhibitors contain a pyrazolo\[3,4-*d*\]pyrimidinone scaffold to establish interactions with these residues *via* hydrogen bonds and *π---π* interactions[@bib23], [@bib24], [@bib25]. Thus, in our newly designed compounds, the pyrazolo\[3,4-*d*\]pyrimidinone scaffold was retained. Besides, a narrow and long pocket consisting of Leu420, Leu421, Tyr424, Phe441, Ala452, and Gln453 existed at the 6-position of this pyrazolo\[3,4-*d*\]pyrimidinone ring, providing suitable space for introducing a fragment. Notably, the pharmacophore of rosiglitazone was attached on this position by using a 2-aminoethanol side chain to occupy the pocket ([Fig. 1](#f0005){ref-type="fig"}).

2.2. Molecular docking and molecular dynamics (MD) simulation studies on the PDE9-designed compounds complexes {#s0020}
--------------------------------------------------------------------------------------------------------------

In order to decide which designed molecules should be synthesized and bioassayed, the putative binding modes and binding free energies of target compounds with PDE9 were predicted by using molecular docking and molecular dynamics simulation methods.

### 2.2.1. Validation of the molecular docking method {#s0025}

In order to validate the reliability of our molecular docking approach surflex-dock embedded in Tripos Sybyl X 2.0.[@bib26], the bound ligand **28s** was extracted from the X-ray structure of PDE9 (PDB ID: 4GH6) and was redocked back into the same receptor with several docking conditions and scoring parameters. The RMSD value between the crystal pose and the top 15 poses for **28s** was below 1.5 Å, indicating that the docking method and its parameters adopted were approximate and suitable for PDE9. Subsequently, all the designed compounds were docked into the same active site pocket of PDE9 with the same procedures used above to generate initial putative binding models for subsequent MD simulations.

### 2.2.2. Binding patterns of the designed compounds with PDE9 after MD simulations {#s0030}

After 8 ns MD simulations, all the PDE9-inhibitor complexes achieved stable MD trajectories. Based on the stable MD binding pattern ([Fig. 2](#f0010){ref-type="fig"}), compound **11a** formed two hydrogen bonds with the residue Gln453 and *π*---*π* stacking interaction with Phe456 as expected. Besides, the fluorine atom possibly formed a hydrogen bond with Phe456[@bib27], which also enabled 2-fluoro phenyl ring to form the edge-face *π---π* interaction with Phe456. In addition to the *π---π* interactions and hydrogen-bonding interactions, hydrophobic and van der Waals interactions between residues Leu420, Tyr424, Phe441, Val417, Ala452, Phe459, Val460, Ile403, Met365, and Ala366 were also observed in the PDE9-**11a** complex.Figure 2Putative binding pattern of the PDE9-**11a** complex after MD simulations.Fig. 2

Both compounds **11c** and **11d** adopted similar binding modes to compound **11a**, forming two hydrogen bonds with Gln453 and strong *π--π* stacking interaction with Phe456. However, compound **11d** lacking the fluoro group, did not form an additional hydrogen bond with Phe456, whereas **11c** kept the hydrogen bond ([Fig. 3](#f0015){ref-type="fig"}A). For the compounds **14d** and **15** with different R~1~ group on the side chain, both of them formed two hydrogen bonds with Gln453. The *π--π* stacking interactions against Phe456 were also observed. The main difference in the binding modes was that the 2,4-thiazolidinedione substituted phenyl ring stretched in different directions ([Fig. 3](#f0015){ref-type="fig"}B).Figure 3(A) Superposition of binding patterns of compounds **11a**, **11c**, and **11d** with PDE9. **11a** in cyan color, **11c** in yellow color, and **11d** in blue color. (B) Superposition of binding patterns of compounds **14d** and **15** with PDE9. **14d** in pink color, **15** in yellow color.Fig. 3

The binding mode of rosiglitazone with PDE9A was also predicted ([Supplementary Information Fig. S1](#s0305){ref-type="sec"}). The 2,4-thiazolidinedione of Rosiglitazone formed three hydrogen bonds with Gln453, Glu406 and Ile403 in the binding pocket of PDE9A protein.

### 2.2.3. Binding free energy calculations of the designed compounds with PDE9 {#s0035}

The predicted binding free energies Δ*G*~bind,pred~ of designed compounds, hit compound **C33** and Rosiglitazone were calculated by the molecular mechanics/Poisson--Boltzmann surface area (MM-PBSA) method ([Table 1](#t0005){ref-type="table"}). Almost all the designed compounds gave higher binding free energies than **C33** and Rosiglitazone. Among these compounds, PDE9-**5a**, PDE9-**5b,** and PDE9-**5c** complexes possessed relatively high Δ*G*~bind,pred~ values of −21.91, −20.75, and −22.60, respectively. In the series of compounds **11**, **14** and **15** with 2,4-thiazolidinedione group substituted, the PDE9-**11a** complex gave the most negative Δ*G*~bind,pred~ value whereas the PDE9-**15** complex exhibited the most positive counterpart (PDE9-**11a**:−36.26 kcal/mol, PDE9-**15**: −24.67 kcal/mol, respectively). The Δ*G*~bind,pred~ values of the PDE9-ligand complexes, such as **11a**, **14a** and **14c** were more negative than these of the others, which implied that these compounds are supposed to be more potent than others. As a result, 12 compounds were retained and subjected to be synthesized and bioassayed.Table 1Predicted binding free energies for the designed compounds with PDE9 by the MM-PBSA Method.Table 1Image 2![](fx2.gif)[^2]

2.3. Synthesis of the designed compounds {#s0040}
----------------------------------------

The synthesis of the designed compounds **5a**--**5c** is shown in [Scheme 1](#f0040){ref-type="fig"}[@bib28]. Firstly, the Boc-protected 2-aminoethanol (**1**) reacted with substituted phenol (**2a**--**2c**) under Mitsunobu-type reaction condition to afford compounds **3a**--**3c**. The Boc groups of **3a**--**3c** were deprotected with trifluoroacetic acid, providing the corresponding amine **4a**--**4c** in quantitate yields, which were then reacted with 6-chloro-1-cyclopentyl-1*H*-pyrazolo\[3,4-*d*\]pyrimidin-4(5*H*)-one to afford compounds **5a**--**5c**[@bib23].Scheme 1The synthesis of the designed compounds **5a--5c**. Reagents and conditions: (a) PPh~3~, DIAD, THF, 0 °C to r.t., overnight; (b) TFA-DCM, 1:3, r.t., 0.5 h; (c) TEA, *i-*PrOH, reflux, overnight.Scheme 1

[Scheme 2](#f0045){ref-type="fig"} shows the synthesis of **11a**--**d**, **14a**--**d** and **15**. The Mitsunobu-type reaction between 2-substituted 4-hydroxylbenzaldehyde **7a**--**e** and Boc-protected 2-aminoethanol **6a**--**6b** afforded intermediate **8**. A following Knoevenagel condensation of thiazolidine-2,4-dione with **8** gave the benzylidene **9**. The intermediate **9** went into the same procedure as **3** to remove the Boc group and subsequently reacted with 6-chloro-1-cyclopentyl-1*H*-pyrazolo\[3,4-*d*\] pyrimidin-4(5*H*)-one, providing compounds **11a**--**d** in moderated yield. The configuration of the exocyclic C=C bond in compounds **11a**--**d** were assigned to be "Z" on the basis of ^1^H NMR spectroscopy, in which the methine proton were detected at 7.70--7.79 ppm in ^1^H NMR spectra[@bib29], [@bib30], [@bib31], [@bib32]. On the other hand, the benzylidene carbon---carbon double bond of **9** was chemoselectively reduced with Mg to afford intermediates **12**. After the removal of the Boc group of **12** in the presence of TFA, the resulting intermediate **13** reacted with 6-chloro-1-cyclopentyl-1*H*-pyrazolo\[3,4-d\]pyrimidin-4(5*H*)-one to furnish the final products **14a**--**d** and **15**.Scheme 2The synthesis of **11a**--**d**, **14a**--**d** and **15**. Reagents and conditions: (a) PPh~3~, DIAD, THF, 0 °C to r.t., overnight; (b) thiazolidine-2,4-dione, piperidine, EtOH, reflux, overnight; (c) TFA-DCM (1:3), r.t., 0.5 h; (d) Mg, MeOH, r.t., 8 h; (e) TEA, *i*-PrOH, reflux, overnight.Scheme 2

2.4. Bioassay validations of the synthesized compounds towards PDE9 in vitro {#s0045}
----------------------------------------------------------------------------

### 2.4.1. Structure--activity relationship of these target compounds {#s0050}

Bioassay validations for the synthesized compounds were performed against PDE9 using the same procedure as we previously reported[@bib17]. BAY 73-6691 serves as the reference compound for the bioassay with IC~50~ of 48 nmol/L, which is close to its literature value of 55 nmol/L. The results for the synthesized compounds were summarized in [Table 2](#t0010){ref-type="table"}. Most of the designed compounds show more potent IC~50~ values than the starting hit **C33** (16 nmol/L, [Fig. 1](#f0005){ref-type="fig"}). Rosiglitazone gave no inhibition against PDE9A even at the concentration of 5 mmol/L.Table 2The IC~50~ values of compounds **5a**--**5c**, **11a**--**11d**, **14a**--**14d**, and **15** against PDE9^a^.Table 2Image 3![](fx3.gif)[^3][^4][^5][^6][^7]

As is mentioned before, the pocket next to the 6-position of pyrimidinone scaffold is narrow and long[@bib23], [@bib24], [@bib25]. Although a flexible ethyl amino side chain with small volume was used to attach the pharmacophore of rosiglitazone on the pyrimidinone scaffold, the volume of tail at this chain may affect compounds to suit this pocket significantly. Thus, compounds **5a**---**5c** were designed and synthesized at the beginning in order to identify the capacity of this pocket. To our delighted, all of them gave remarkable inhibitory activities against PDE9 including compound **5c** with quinoline as the tail. The IC~50~ values of compounds **5b** and **5c** were even higher than that of **5a**, indicating that the substitution at the 2-position of phenyl ring might form additional interactions with residues in the pocket of PDE9.

Summary of the structure---activity relationships (SARs) for these compounds is depicted in [Fig. 4](#f0020){ref-type="fig"}. Compounds **11a**--**d** and **14a**--**d** were synthesized with the 2,4-thiazolidinediones attached on the phenyl ring with double or single carbon---carbon bond in the following modification. In the series of compounds **11a**--**d**, the IC~50~ values ranged from 1.1 to 76 nmol/L. Compound **11a** with 2-fluoro on the phenyl ring gave the best IC~50~ of 1.1 nmol/L, which is 8- and 48-fold potent than those of PF-04447943 and BAY 73-6691, respectively. Compared with compound **5b**, the IC~50~ of **11a** increased 20 fold, indicating that the 2,4-thiazolidinediones enhanced the affinity of compounds with PDE9. Furthermore, in order to identify our speculation that the substitution at the 2-position of phenyl ring might form additional interactions with PDE9A, **11b** with 2-trifluoromethyl, **11c** with 2-fluoro-6-methoxy, and **11d** with 2-methoxy groups substituted on the phenyl ring were synthesized and evaluated. All of them gave better inhibitory potencies than compound **5a**--**5c** except **11d**. Since the volume of 2,4-thiazolidinedione-phenyl ring in **11c** is larger than that of **11d**, we concluded that the interactions formed by fluorine atom with PDE9, instead of steric hindrance, should be the main reason for the enhanced inhibitory activities of these compounds. The alternation of carbon--carbon double bonds of compounds **11a**--**c** to form compounds **14a**--**c** with carbon---carbon single bonds, caused slight decrease in inhibitory activities (**11** *vs* **14**), the IC~50~ of which ranged from 3.5 to 8.8 nmol/L.Figure 4Summary of the structure---activity relationships of PDE9 inhibitors.Fig. 4

Compound **15** with a methyl group at the R~1~ position was also synthesized and evaluated to explore the effect of linkers with different volumes. Compared with **14d**, the IC~50~ of compound **15** dropped to 98 nmol/L. Combining the results of compounds **5a**--**5c**, we speculated that the substitutions on the R position affect the spatial orientation of the side chain, so that the side chain cannot fit the pocket well.

### 2.4.2. The experimental measurements for the IC~50~ values are consistent with ΔG~bind,pred~ as expected {#s0055}

Among these targeted compounds, **11a** exhibited the best potency with the IC~50~ value of 1.1 nmol/L, which also showed the most negative predicted binding free energy Δ*G*~bind,pred~ (−36.26 kcal/mol). The \|Δ*G*~bind,pred~\| values of the PDE9-**11a**, PDE9-**11c**, PDE9-**14a,** and PDE9-**14c** complexes were higher than those of the others, while the IC~50~ of these compounds against PDE9 were better than others (below 5 nmol/L). As we expected, the biological affinities of the PDE9-ligand complexes correlate well with their Δ*G*~bind,pred~ values.

The Δ*G*~bind,pred~ values were −36.26 and −24.67 kcal/mol for the PDE9-**11a** and PDE9-**15** complexes, respectively, which may account for their differences in the IC~50~ values (1.1 and 98 nmol/L). Compared with compound **11a**, the inhibitory activity of compound **11c** almost remained unchanged while **11d** dropped with the IC~50~ of 76 nmol/L. The predicated binding mode of the PDE9A-**11c** complex validated our speculation that the steric hindrance of the substitution is not the main reason for the dropped affinity with PDE9 ([Fig. 3](#f0015){ref-type="fig"}A). Both compounds **11c** and **11d** adopted similar binding modes to **11a**. Two hydrogen bonds with Gln453 and *π---π* stacking with Phe456 are formed by all of them; however, compound **11d** lacking the fluoro group, did not form additional hydrogen bond with Phe456. This is coincided with the decreasing affinity of **11d** with PDE9.

### 2.4.3. A significantly linear relationship was achieved between ΔG~bind,exp~ and ΔG~bind,pred~ {#s0060}

A significantly linear correlation is achieved ([Fig. 5](#f0025){ref-type="fig"}) with a conventional regression coefficient (*R*^2^ = 0.8379) based on Δ*G*~bind,pred~ and Δ*G*~bind,exp~, which are approximately estimated from the *in vitro* IC~50~ values (*via* Δ*G*~bind,exp~ ≈ RTlnIC~50~) for nine PDE9 inhibitor complexes with similar functional groups. This statistically significant relationship suggests that the Δ*G*~bind,pred~ values for the PDE9 inhibitor complexes *via* binding free energy prediction after MD simulations can be used to prognosticate the experimental inhibitory potencies for newly designed PDE9 inhibitors with a similar scaffold. Since the entropic contribution to the binding free energy was ignored due to huge computational consumption, the Δ*G*~bind,pred~ values were more negative than those (Δ*G*~bind,exp~) approximately estimated from the experimental IC~50~ values ([Table 2](#t0010){ref-type="table"}). However, it is still meaningful to compare their relative magnitudes, which is common in the literature[@bib33], [@bib34], [@bib35].Figure 5The correlation between predicted binding free energies and experimental binding free energies for nine compounds with 2, 4-thiazolidinedione (**11a**--**11d**, **14a**--**14d** and **15**).Fig. 5

### 2.4.4. Binding free energy decomposition {#s0065}

[Table 3](#t0015){ref-type="table"} lists the Δ*G*~bind,pred~ values predicted by MM-PBSA and the decomposition of energy terms to the PDE9-**11a** and PDE9-**15** complexes, which were calculated by averaging over 100 snapshots for the finial 1.0 ns (every 10 ps) MD simulations. Obviously, the Δ*G*~ele~, Δ*G*~vdw~, and Δ*G*~ele,solc~ components make the major contributions to the total binding free energy. The energy terms for van der Waals interactions (Δ*G*~vdw~) and polar contribution to solvation (Δ*G*~ele,sol~) of the PDE9-**11a** complex are 4.1 and 5.4 kcal/mol lower than those for the PDE9-**15** complex. We speculated that the van der Waals interactions might play an important role for the enhanced inhibition activity as well as the polar contribution.Table 3Components of the predicted binding free energies from their trajectories for binding of **11a** or **15** to PDE9 by the MM-PBSA method.Table 3Energy terms (kcal/mol)**11a15**Δ*G*~ele~[a](#tbl3fna){ref-type="table-fn"}−23.54±3.47−21.87±4.21Δ*G*~vdw~[b](#tbl3fnb){ref-type="table-fn"}−53.89±3.90−49.84±3.09Δ*G*~nonpol,sol~[c](#tbl3fnc){ref-type="table-fn"}−7.05±0.18−6.58±0.25Δ*G*~ele,sol~[d](#tbl3fnd){ref-type="table-fn"}48.22±5.8453.63±5.98Δ*G*~bind,pred~[e](#tbl3fne){ref-type="table-fn"}−36.26±5.49−24.67±4.99[^8][^9][^10][^11][^12]

To further evaluate the effects of energy on the contributions of each residue in the binding-site pocket, residue-based energy decomposition for the binding free energies between the ligands and PDE9A was conducted by use of the MM-PBSA method. [Fig. 6](#f0030){ref-type="fig"} shows the energy decomposition for key residues in the two complexes (**11a**-PDE9A and **15**-PDE9A).Figure 6Decomposition of the key residue contributions to the binding free energies for the complexes of PDE9 with **11a** and **15**.Fig. 6

Generally, if the interaction energy between a ligand and a residue is lower than −1 kcal/mol, the residue is viewed to be important in the molecular recognition of ligands. Our results suggested that the following residues might be important for inhibitory activities of **11a** and **15** on PDE9: Phe456 (−5.2 and −4.5 kcal/mol), Gln453 (−4.4 and −4.3 kcal/mol), Leu420 (−2.4 and −2.2 kcal/mol), Ile403 (−1.9 and −2.0 kcal/mol), Tyr424 (−1.8 and −1.4 kcal/mol), Met365 (−1.3 and −1.0 kcal/mol), Val460 (−1.3 and −0.3 kcal/mol), Phe441 (−1.2 and −2.4 kcal/mol) and Phe459 (−1.1 and −0.2 kcal/mol). Among these residues, Phe456 and Gln453 contributed most to the total binding free energies, in consistence with the binding patterns that all the ligands formed *π--π* stacking with Phe456 and hydrogen bonds with Gln453. Phe456, Phe459 and Val460 in the hydrophobic pocket made the major difference in energy contribution. Phe456, Phe459 and Val460 contribute to the PDE9-**11a** complex with the binding free energies of 0.7, 0.9 and 1.0 kcal/mol lower than those of PDE9-**15**, which is consistent with the binging modes that the 2,4-thiazolidinedione substituted phenyl ring stretched in different position ([Supplementary Information Fig. S2](#s0305){ref-type="sec"}). Additionally, **11a** involves hydrophobic interactions with the adjacent residues Leu420, Ile403, Tyr424, Met365, Val460, Phe441, and Phe459, which achieves more than 1 kcal/mol enhancement of the energy favorable to the total binding free energy. And all of these involve van der Waals contacts with **11a**. This might be the reason why the Δ*G*~vdw~ term for **11a** is −53.89 kcal/mol.

2.5. Effects of synthesized compounds on the cell viability {#s0070}
-----------------------------------------------------------

Compounds **11a**, **11c**, **14a**, and **14c** with IC~50~ against PDE9 below 5 nmol/L were subjected to MTT assay by using the human neuroblastoma cell line SH-SY5Y to examine the cytotoxic effects[@bib36]. The cell viabilities of compound **11a** (PDE9 IC~50~: 1.1 nmol/L) at the concentration of 100 and 40 μmol/L were 34% and 55%, respectively. The cell viabilities of compound **11c** (PDE9 IC~50~: 3.3 nmol/L) at the concentration of 100 and 40 μmol/L were 57% and 84%, respectively. The cell viabilities of compound **14a** (PDE9 IC~50~: 3.5 nmol/L) at the concentration of 100 and 40 μmol/L were 52% and 82%, respectively. The cell viabilities of compound **14c** (PDE9 IC~50~: 4.2 nmol/L) at the concentration of 100 and 40 μmol/L were 62% and 93%, respectively. These results ([Fig. 7](#f0035){ref-type="fig"}) indicated that all these compounds were almost nontoxic and suitable for further *in vivo* exploration.Figure 7Cell viability of compounds **11a, 11c, 14a**, and **14c** by using human neuroblastoma cell line SH-SY5Y.Fig. 7

3. Conclusions {#s0075}
==============

In summary, a series of novel PDE9 inhibitors have been rationally designed, synthesized, and evaluated. Four of the designed compounds have the IC~50~ below 5 nmol/L, which also showed low toxicity to SH-SY5Y cells. Compound **11a** had the best potency to inhibit PDE9 with the IC~50~ of 1.1 nmol/L, which is 8- and 48-fold more potent than the candidates PF-04447943 and BAY 73-6691, respectively. The bioassay results were in accordance with binding free energy analysis results as expected, providing evidences for further structural modification.

4. Experimental section {#s0080}
=======================

All the starting materials and reagents were purchased from commercial suppliers and used directly without further purification. Column chromatography was performed using silica gel (200--300 mesh) purchased from Qingdao Haiyang Chemical Co., Ltd. Thin-layer chromatography was performed on precoated silica gel F-254 plates (0.25 mm, Qingdao Haiyang Chemical Co., Ltd.) and was visualized with UV light. ^1^H NMR and ^13^C NMR spectra were recorded on a BrukerBioSpin GmbH spectrometer at 400.1 and 100.6 MHz, respectively. Coupling constants are given in Hz. MS spectra were obtained on an Agilent LC--MS 6120 instrument. The purity of tested compounds was determined by reverse-phase high-performance liquid chromatography (HPLC) analysis. HPLC instrument: SHIMADZU LC-20AT (column: Hypersil BDS C18, 5.0 μm, 150 mm × 4.6 mm (Elite); Detector: SPD-20A U*V/V*IS detector, UV detection at 254 nm; Elution, MeOH in water (70%, *v/v*); T = 25 °C; and flow rate = 1.0 mL/min. High-resolution mass spectra (HR-MS) were obtained on a LT-TOF.

4.1. General procedure for the synthesis of compounds **3a**--**3c**[@bib28] {#s0085}
----------------------------------------------------------------------------

*tert*-Butyl(2-hydroxyethyl)carbamate **1** (0.65 g, 4.0 mmol), substituted 4-hydroxybenzaldehyde **2a***--***2c** (4.0 mmol) and triphenylphosphine (1.6 g, 6.0 mmol) were dissolved in anhydrous THF (40 mL). The mixture was cool to 0 °C. DIAD (1.2 mL, 6.0 mmol) was added dropwise. The mixture was stirred overnight at ambient temperature. After the reaction was finished, the mixture was extracted with ethyl acetate three times and washed with saturated NH~4~Cl aqueous solution. The organic layer was collected, dried over anhydrous Na~2~SO~4~, filtered, concentrated under vacuum and purified by silica column chromatography to afford **3a***--***3c** as colorless oil.

### 4.1.1. *tert*-Butyl(2-phenoxyethyl)carbamate (**3a**) {#s0090}

Colorless oil, Yield 67%; ^1^H NMR (400 MHz, CDCl~3~), *δ* 7.27 (m, 3H), 6.97 (m, 1H), 6.87 (m, 2H), 4.02 (t, 2H, *J*= 9.3 Hz), 3.52 (m, 2H), 1.45 (s, 9H).

### 4.1.2. *tert*-Butyl(2-(2-fluorophenoxy)ethyl)carbamate (**3b**) {#s0095}

Colorless oil, Yield 64%; ^1^H NMR (400 MHz, CDCl~3~), *δ* 7.05 (m, 3H), 6.91 (m, 1H), 6.21 (s, 1H), 4.24 (m, 2H), 3.92 (m, 2H), 1.46 (s, 9H).

### 4.1.3. *tert*-Butyl(2-(quinolin-8-yloxy)ethyl)carbamate (**3c**) {#s0100}

Colorless oil, Yield 78%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 8.88 (dd, *J* = 4.2, 1.6 Hz, 1H), 8.15 (dd, *J* = 8.3, 1.5 Hz, 1H), 7.44 (m, 3H), 7.08 (m, 1H), 6.36 (s, 1H), 4.26 (t, *J* = 4.9 Hz, 2H), 3.71 (dd, *J* = 10.1, 5.1 Hz, 2H), 1.46 (s, 9H).

4.2. General procedure for the synthesis of compounds **5a**--**5c**[@bib24], [@bib28] {#s0105}
--------------------------------------------------------------------------------------

Compounds **3a***--***3c** (0.30 mmol) was dissolved in 25% TFA in dichloromethane (2.0 mL). The mixture was then stirred at ambient temperature for 0.5 h. The solvent was removed by evaporation and the residue was washed with petroleum ether/ethyl acetate (2:1, *v/v*), and evaporated again. The resulting product **4a***--***4c** was directly used for the next reaction step without further purification. To a sealed tube were added isopropanol (2.5 mL), 6-chloro-1-cyclopentyl-1*H*-pyrazolo\[3,4-*d*\]pyrimidin-4(5*H*)-one (0.25 mmol), **4a***--***4c** (0.30 mmol), and triethylamine (76 mg, 0.75 mmol). The reaction mixture was reflux overnight. The solvent was removed *in vacuo*. The residue was purified by silica column chromatography to provide the final product **5a**--**5c** as white solids.

### 4.2.1. 1-Cyclopentyl-6-((2-phenoxyethyl)amino)-1H-pyrazolo\[3,4-d\]pyrimidin-4(5H)-one (**5a**) {#s0110}

White solid, Yield: 46%; Purity: 98%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 10.96 (s, 1H), 7.79 (s, 1H), 7.14 (t, *J* = 7.9 Hz, 2H), 6.82 (m, 3H), 6.60 (t, *J* = 5.3 Hz, 1H), 4.93 (p, *J* = 7.5 Hz, 1H), 4.08 (t, *J* = 5.3 Hz, 2H), 3.77 (dd, *J* = 10.6, 5.2 Hz, 2H), 2.01 (m, 4H), 1.87 (m, 2H), 1.63 (m, 2H). ^13^C NMR (101 MHz, CDCl~3~) *δ* 160.60, 158.48, 154.37, 152.93, 134.31, 129.48, 121.14, 114.64, 99.91, 66.24, 57.41, 40.51, 32.06, 24.83. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~18~H~21~N~5~O~2~ 340.1768, Found 340.1763.

### 4.2.2. 1-Cyclopentyl-6-((2-(2-fluorophenoxy)ethyl)amino)-1H-pyrazolo\[3,4-d\]pyrimidin-4(5H)-one (**5b**) {#s0115}

White solid, Yield: 51%; Purity: 97%;^1^H NMR (400 MHz, CDCl~3~) *δ* 11.23 (s, 1H), 7.88 (s, 1H), 7.05 (m, 3H), 6.91 (m, 1H), 6.21 (s, 1H), 5.01 (dt, *J* = 15.2, 7.6 Hz, 1H), 4.26 (m, 2H), 3.90 (m, 2H), 2.08 (m, 4H), 1.95 (m, 2H), 1.72 (m, 2H). ^13^C NMR (101 MHz, CDCl~3~) *δ* 160.71, 154.26, 152.82, 134.36, 124.32, 124.29, 121.92, 121.85, 116.50, 116.32, 115.79, 99.97, 68.05, 57.39, 40.49, 32.02, 24.80. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~18~H~20~N~5~O~2~F 358.1674, Found 358.1657.

### 4.2.3. 1-Cyclopentyl-6-((2-(quinolin-8-yloxy)ethyl)amino)-1H-pyrazolo\[3,4-d\]pyrimidin-4(5H)-one (**5c**) {#s0120}

White solid, Yield: 58%; Purity: 97%;^1^H NMR (400 MHz, CDCl~3~) *δ* 10.97 (s, 1H), 8.76 (d, *J* = 2.8 Hz, 1H), 8.06 (d, *J* = 7.4 Hz, 1H), 7.79 (m, 2H), 7.36 (m, 3H), 7.03 (d, *J* = 7.4 Hz, 1H), 4.98 (m, 1H), 4.34 (t, *J* = 4.8 Hz, 2H), 4.01 (d, *J* = 4.6 Hz, 2H), 2.07 (m, 4H), 1.93 (m, 2H), 1.70 (m, 2H).^13^C NMR (101 MHz, CDCl~3~) *δ* 160.57, 154.23, 153.95, 152.84, 148.63, 139.49, 136.51, 134.37, 129.46, 126.82, 121.73, 120.04, 109.15, 99.92, 67.28, 57.19, 40.14, 32.03, 24.82. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~21~H~22~N~6~O~2~ 391.1877, Found 391.1833.

4.3. General procedure for the synthesis of compounds **8a**---**8f** {#s0125}
---------------------------------------------------------------------

*tert*-Butyl(2-hydroxyethyl)carbamate **6a***--***6b** (4.0 mmol), substituted 4-hydroxy-2-formylbenzaldehyde **7a***--***7d** (4.0 mmol) and triphenylphosphine (1.6 g, 6.0 mmol) were dissolved in anhydrous THF (40 mL). The mixture was cool to 0 °C. DIAD (1.2 mL, 6.0 mmol) was added dropwise. The mixture was stirred overnight at ambient temperature. After the reaction was finished, the mixture was diluted with ethyl acetate three times and washed with saturated NH~4~Cl aqueous solution. The organic layer was collected, dried over anhydrous Na~2~SO~4~, filtered, concentrated under vacuum and purified by silica column chromatography to afford **8a***--***8f** as colorless oil.

### 4.3.1. *tert*-Butyl(2-(2-fluoro-4-formylphenoxy)ethyl)carbamate (**8a**) {#s0130}

Colorless oil, Yield 63%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 9.87 (d, *J* = 2.1 Hz, 1H), 7.63 (m, 2H), 7.09 (t, *J* = 8.2 Hz, 1H), 5.09 (s, 1H), 4.19 (t, *J* = 5.1 Hz, 2H), 3.61 (dd, *J* = 10.9, 5.4 Hz, 2H), 1.47 (s, 9H).

### 4.3.2. *tert*-Butyl(2-(4-formyl-2-(trifluoromethyl)phenoxy)ethyl)carbamate (**8b**) {#s0135}

Colorless oil, Yield 60%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 9.93 (s, 1H), 8.13 (d, *J* = 1.6 Hz, 1H), 8.05 (d, *J* = 8.6 Hz, 1H), 7.12 (d, *J* = 8.6 Hz, 1H), 4.98 (s, 1H), 4.22 (t, *J* = 5.0 Hz, 2H), 3.61 (d, *J* = 5.5 Hz, 2H), 1.45 (s, 9H).

### 4.3.3. *tert*-Butyl(2-(2-fluoro-4-formyl-6-methoxyphenoxy)ethyl)carbamate (**8c**) {#s0140}

Colorless oil, Yield 55%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 9.86 (d, *J* = 1.1 Hz, 1H), 7.28 (m, 2H), 5.36 (s, 1H), 4.23 (t, *J* = 4.9 Hz, 2H), 3.97 (s, 3H), 3.48 (dd, *J* = 10.3, 5.2 Hz, 2H), 1.46 (s, 9H).

### 4.3.4. *tert*-Butyl(2-(4-formyl-2-methoxyphenoxy)ethyl)carbamate (**8d**) {#s0145}

Colorless oil, Yield 68%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 9.61 (s, 1H), 7.09 (d, *J* = 8.3, 1H), 7.00 (d, *J* = 8.3 Hz, 1H), 6.10 (s, 1H), 3.98 (s, 3H), 4.10 (m, 2H), 3.54 (m, 2H), 1.46 (s, 9H).

### 4.3.5. *tert*-Butyl(2-(4-formylphenoxy)ethyl)carbamate (**8e**) {#s0150}

Colorless oil, Yield 63%; ^1^H NMR (400 MHz, CDCl~3~) ^1^H NMR (400 MHz, CDCl~3~) *δ* 9.89 (d, *J* = 4.2 Hz, 1H), 7.85 (m, 2 H), 7.01 (m, 3H), 4.12 (d, *J* = 4.7 Hz, 2H), 3.58 (s, 2H), 1.46 (s, 9H).

### 4.3.6. *tert*-Butyl(1-(4-formylphenoxy)propan-2-yl)carbamate (**8f**) {#s0155}

Colorless oil, Yield 51%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 9.90 (s, 1H), 7.87--7.85 (m, 1H), 7.84 (d, *J* = 2.0 Hz, 1H), 7.06--7.03 (m, 1H), 7.02 (d, *J* = 1.8 Hz, 1H), 4.77 (s, 1H), 4.05 (d, *J* = 9.2 Hz, 2H), 1.47 (s, 9H), 1.32 (d, *J* = 6.7 Hz, 3H).

4.4. General procedure for the synthesis of compounds **9a**--**9f** {#s0160}
--------------------------------------------------------------------

To a solution of **8a***--***8f** (1.5 mmol) and 2,4-thiazolidinedione (0.19 g, 1.6 mmol) in anhydrous ethanol (6.0 mL) were added piperidine (45 μL, 0.45 mmol). The reaction mixture was heated at reflux for 12 h. The mixture was concentrated under vacuum and purified by silica column chromatography to yield **9a***--***9f** as a white solid.

### 4.4.1. (Z)-*tert*-Butyl(2-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-fluorophenoxy)ethyl)carbamate (**9a**) {#s0165}

White solid, Yield 68%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 12.57 (s, 1H), 7.74 (s, 1H), 7.49 (dd, *J* = 12.5, 1.8 Hz, 1H), 7.36 (m, 2H), 7.01 (s, 1H), 4.13 (m, 2H), 3.33 (m, 2H), 1.38 (s, 9H).

### 4.4.2. (Z)-*tert*-Butyl(2-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-(trifluoromethyl)phenoxy)ethyl)carbamate (**9b**) {#s0170}

Yellow solid, Yield 66%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 7.78 (s, 1H), 7.72 (s, 1H), 7.64 (d, *J* = 8.9 Hz, 1H), 7.27 (s, 1H), 7.10 (d, *J* = 8.5 Hz, 1H), 4.19 (m, 2H), 3.60 (m, 2H), 1.45 (s, 9H).

### 4.4.3. (Z)-*tert*-Butyl(2-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-fluoro-6-methoxyphenoxy)ethyl)carbamate (**9c**) {#s0175}

White solid, Yield 49%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 12.64 (s, 1H), 7.74 (s, 1H), 7.10 (dd, *J* = 15.5, 4.3Hz, 2H), 6.82 (s, 1H), 4.04 (t, *J* = 6.1 Hz, 2H), 3.88 (s, 3H), 3.23 (dd, *J* = 11.7, 5.9 Hz, 2H), 1.37 (s, 9H).

### 4.4.4. (Z)-*tert*-Butyl(2-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-methoxyphenoxy)ethyl)carbamate (**9d**) {#s0180}

Yellow solid, Yield 70%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 7.82 (s, 1H), 7.09 (dd, *J* = 8.3, 1.9 Hz, 1H), 7.00 (d, *J* = 8.3 Hz, 2H), 6.10 (s, 1H), 3.95 (s, 3H), 3.88 (m, 2H), 3.43 (m, 2H), 1.40 (s, 9H).

### 4.4.5. (Z)-*tert*-Butyl (2-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenoxy)ethyl)carbamate (**9e**) {#s0185}

White solid, Yield 47%; ^1^H NMR (400 MHz, MeOD) *δ* 7.75 (d, *J* = 8.4 Hz, 1H), 7.52 (m, 2H), 7.09 (m, 2H), 4.10 (m, 2H), 3.47 (t, *J* = 5.6 Hz, 2H), 1.46 (s, 9H).

### 4.4.6. (Z)-*tert*-Butyl(1-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenoxy)propan-2-yl)carbamate (**9f**) {#s0190}

White solid, Yield 72%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 9.23 (s, 1H), 7.76 (s, 1H), 7.44 (d, *J* = 8.4 Hz, 2H), 7.00 (d, *J* = 8.5 Hz, 2H), 4.01 (s, 2H), 1.71 (s, 1H), 1.49 (s, 9H), 1.32 (d, *J* = 6.8 Hz, 3H).

4.5. General procedure for the synthesis of compounds **11a**--**11d** {#s0195}
----------------------------------------------------------------------

Compound **9a***--***d** (0.30 mmol) was dissolved in 25% TFA in dichloromethane (2.0 mL). The mixture was then stirred at ambient temperature for 0.5 h. The solvent was removed by evaporation and the residue was washed with petroleum ether/ethyl acetate (2:1, *v/v*), and evaporated again. The resulting product **10a***--***10d** was directly used for the next reaction step without further purification. To a 10 mL of sealed vial were added isopropanol (2.5 mL), 6-chloro-1-cyclopentyl-1*H*-pyrazolo\[3,4-*d*\]pyrimidin-4(5*H*)-one (0.25 mmol), **10a***--***10d** (0.30 mmol), and triethylamine (76 mg, 0.75 mmol). The reaction mixture was reflux overnight. The solvent was removed *in vacuo*. The residue was purified by silica column chromatography to provide the final product **11a***--***11d** as white solids.

### 4.5.1. (Z)-5-(4-(2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo\[3,4-d\]pyrimidin-6-yl)amino)ethoxy)-3-fluorobenzylidene)thiazolidine-2,4-dione (**11a**) {#s0200}

White solid, Yield 33%; Purity: 98%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 12.58 (s, 1H), 10.53 (s, 1H), 7.74 (s, 2H), 7.51 (d, *J* = 13.2 Hz, 1H), 7.41 (m, 2H), 6.74 (t, *J* = 5.5 Hz, 1H), 4.88 (m, 1H), 4.33 (t, *J* = 5.5 Hz, 2H), 3.76 (dd, *J* = 10.8, 5.3 Hz, 2H), 1.99 (m, 2H), 1.91 (m, 2H), 1.83 (m, 2H), 1.62 (m, 2H). ^13^C NMR (101 MHz, DMSO-*d*~6~) *δ* 168.26, 167.96, 158.24, 153.87, 153.75, 148.42, 148.31, 134.35, 130.98, 127.37, 126.82, 122.82, 118.27, 118.07, 115.77, 100.25, 67.83, 56.98, 32.18, 24.78. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~22~H~21~N~6~O~4~FS 485.1402, Found 485.1383.

### 4.5.2. (Z)-5-(4-(2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo\[3,4-d\]pyrimidin-6-ylamino)ethoxy)-3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione (**11b**) {#s0205}

White solid, Yield 40%; Purity: 93%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 12.64 (s, 1H), 10.67 (s, 1H), 7.89 (s, 1H), 7.83 (m, 2 H), 7.74 (s, 1H), 7.52 (d, *J* = 8.9 Hz, 1H), 6.59 (t, *J* = 5.2 Hz, 1H), 4.80 (dd, *J* = 14.5, 7.3 Hz, 1H), 4.39 (t, *J* = 5.4 Hz, 2H), 3.77 (dd, *J* = 10.9, 5.2 Hz, 2H), 1.95 (m, 2H), 1.88 (m, 2H), 1.81 (m, 2H), 1.59 (m, 2H). ^13^C NMR (101 MHz, Acetone) *δ* 168.11, 166.81, 157.83, 153.72, 153.30, 135.15, 133.72, 130.31, 129.29, 129.24, 129.19, 126.02, 123.01, 122.98, 114.39, 100.30, 67.67, 57.08, 39.92, 31.79, 24.52. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~23~H~21~N~6~O~4~F~3~S 531.1370, Found 531.1355.

### 4.5.3. (Z)-5-(4-(2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo\[3,4-d\]pyrimidin-6-yl)amino)ethoxy)-3-fluoro-5-methoxybenzylidene)thiazolidine-2,4-dione (**11c**) {#s0210}

White solid, Yield 31%; Purity: 95%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 12.63 (s, 1H), 10.58 (s, 1H), 7.74 (s, 2H), 7.11 (m, 1 H), 6.63 (t, *J* = 5.5 Hz, 1H), 4.84 (dd, *J* = 14.3, 6.7 Hz, 1H), 4.24 (t, *J* = 5.4 Hz, 2H), 3.85 (s, 3H), 3.64 (dd, *J* = 11.0, 5.4 Hz, 2H), 1.97 (m, 2H), 1.90 (m, 2H), 1.82 (m, 2H), 1.60 (m, 2H). ^13^C NMR (101 MHz, DMSO-*d*~6~) *δ* 168.16, 166.19, 158.26, 154.44, 154.41, 154.30, 153.88, 153.73, 153.71, 134.33, 131.02, 111.48, 110.86, 100.23, 72.24, 57.01, 56.88, 32.15, 24.79. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~23~H~23~N~6~O~5~FS 515.1507, Found 515.1496.

### 4.5.4. (Z)-5-(4-(2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo\[3,4-d\]pyrimidin-6-yl)amino)ethoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione (**11d**) {#s0215}

Yellow solid, Yield 25%; Purity: 95%; ^1^H NMR (400 MHz, DMSO) *δ* 10.61 (s, 1H), 9.95 (s, 1H), 7.79 (s, 1H), 7.68 (s, 1H), 7.13 (d, *J* = 1.6 Hz, 1H), 7.04 (dd, *J* = 8.3, 1.5 Hz, 1H), 6.91 (d, *J* = 8.3 Hz, 1H), 6.61 (t, *J* = 5.8 Hz, 1H), 4.86 (m, 1H), 3.88 (m, 2H), 3.80 (s, 3H), 3.63 (dd, *J* = 10.1, 5.5 Hz, 2H), 1.94 (m, 2H), 1.85 (m, 2H), 1.78 (m, 2H), 1.58 (m, 2H). ^13^C NMR (101 MHz, DMSO) *δ* 168.10, 166.42, 158.35, 153.96, 153.92, 151.94, 150.09, 148.47, 134.21, 133.82, 124.81, 124.71, 117.51, 116.71, 114.68, 100.16, 56.89, 56.14, 32.16, 24.70. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~23~H~24~N~6~O~5~S 497.1602, Found 497.1585.

4.6. General procedure for the synthesis of compound **12a**--**12c**, **12e** and **12f** {#s0220}
------------------------------------------------------------------------------------------

Magnesium (0.48 g, 20 mmol) was added to a solution of **9a**--**c**, **9e** and **9f** (0.36 g, 1.0 mmol) in anhydrous methanol (10 mL). The reaction mixture was stirred at room temperature for 8 h. After completion of the reaction, the mixture was quenched by adding saturated NH~4~Cl aqueous solution and extracted with ethyl acetate. The organic layers and extracts were combined, dried over anhydrous Na~2~SO~4~, filtered and concentrated *in vacuo* to afford **12a***--***12c**, **12e** and **12f** as white solids.

### 4.6.1. *tert*-Butyl(2-(4-((2,4-dioxothiazolidin-5-yl)methyl)-2-fluorophenoxy)ethyl)carbamate (**12a**) {#s0225}

White solid, Yield 95%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 7.07 (m, 2H), 6.97 (d, *J* = 6.7 Hz, 2H), 4.57 (dd, *J* = 9.4, 4.1 Hz, 1H), 4.01 (t, *J* = 5.7 Hz, 2H), 3.33 (m, 3H), 2.90 (dd, *J* = 14.2, 9.5 Hz, 1H), 1.39 (s, 9H).

### 4.6.2. tert-Butyl(2-(4-((2,4-dioxothiazolidin-5-yl)methyl)-2-(trifluoromethyl)phenoxy)ethyl)carbamate (**12b**) {#s0230}

White solid, Yield 84%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 9.51 (s, 1H), 7.44 (d, *J* = 1.7 Hz, 1H), 7.36 (d, *J* = 8.5 Hz, 1H), 6.95 (d, *J* = 8.5 Hz, 1H), 4.50 (dd, *J* = 9.2, 4.1 Hz, 1H), 4.10 (t, *J* = 5.0 Hz, 2H), 3.56 (d, *J* = 4.9 Hz, 2H), 3.47 (dd, *J* = 14.3, 4.0 Hz, 1H), 3.15 (dd, *J* = 14.3, 9.2 Hz, 1H), 1.44 (s, 9H).

### 4.6.3. tert-Butyl(2-(4-((2,4-dioxothiazolidin-5-yl)methyl)-2-fluoro-6-methoxyphenoxy)ethyl)carbamate (**12c**) {#s0235}

Light yellow solid, Yield 78%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 6.61 (m, 3H), 4.48 (dd, *J* = 9.5, 3.8 Hz, 1H), 4.09 (d, *J* = 4.8 Hz, 2H), 3.87 (s, 3H), 3.41 (m, 3H), 3.08 (dd, *J* = 13.9, 9.8 Hz, 1H), 1.45 (s, 9H).

### 4.6.4. *tert*-Butyl(2-(4-((2,4-dioxothiazolidin-5-yl)methyl)phenoxy)ethyl)carbamate (**12e**) {#s0240}

White solid, Yield 76%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 8.85 (s, 1H), 7.14 (d, *J* = 8.5 Hz, 2H), 6.84 (d, *J* = 8.5 Hz, 2H), 5.03 (s, 1H), 4.49 (dd, *J* = 9.4, 3.8 Hz, 1H), 4.12 (q, *J* = 7.1 Hz, 1H), 4.00 (t, *J* = 5.0 Hz, 2H), 3.53 (d, *J* = 4.7 Hz, 2H), 3.45 (dd, *J* = 14.2, 3.8 Hz, 1H), 3.10 (dd, *J* = 14.2, 9.5 Hz, 1H), 1.45 (s, 9H).

### 4.6.5. *tert*-Butyl(1-(4-((2,4-dioxothiazolidin-5-yl)methyl)phenoxy)propan-2-yl)carbamate(**12f**) {#s0245}

White solid, Yield 65%; ^1^H NMR (400 MHz, CDCl~3~) *δ* 7.14 (d, *J* = 8.3 Hz, 2H), 6.85 (d, *J* = 8.3 Hz, 2H), 4.47 (d, *J* = 9.0 Hz, 1H), 3.91 (s, 2H), 3.44 (dd, *J* = 14.2, 3.7 Hz, 1H), 3.11 (d, *J* = 11.5 Hz, 1H), 1.45 (s, 9H), 1.28 (d, *J* = 6.7 Hz, 3H).

4.7. General procedure for the synthesis of compound **14a**---**14d**, **15** {#s0250}
------------------------------------------------------------------------------

Compounds **12a***--***12f** (0.30 mmol) was dissolved in 25% TFA in dichloromethane (2.0 mL). The mixture was then stirred at ambient temperature for 0.5 h. The solvent was removed by evaporation and the residue was washed with petroleum ether/ethyl acetate (2:1, *v/v*), and evaporated again. The resulting product **13a***--***13f** was directly used for the next reaction step without further purification. To a 10 mL of sealed vial were added isopropanol (2.5 mL), 6-chloro-1-cyclopentyl-1*H*-pyrazolo\[3,4-*d*\]pyrimidin-4(5*H*)-one (0.25 mmol), **13a***--***13f** (0.30 mmol), and triethylamine (76 mg, 0.75 mmol). The reaction mixture was reflux overnight. The solvent was removed *in vacuo*. The residue was purified by silica column chromatography to provide the final product **14a***--***14d** and **15**.

### 4.7.1. 5-(4-(2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo\[3,4-d\]pyrimidin-6-yl)amino)ethoxy)-3-fluorobenzyl)thiazolidine-2,4-dione (**14a**) {#s0255}

Light yellow solid, Yield 38%; Purity: 96%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 12.01 (s, 1H), 10.50 (s, 1H), 7.75 (s, 1H), 7.18 (t, *J* = 8.8 Hz, 1H), 7.14 (dd, *J* = 12.5, 2.0 Hz, 1H), 7.00 (d, *J* = 8.4 Hz, 1H), 6.73 (t, *J* = 5.3 Hz, 1H), 4.91 (m, 2H), 4.21 (t, *J* = 5.5 Hz, 2H), 3.72 (dd, *J* = 11.2, 5.5 Hz, 2H), 3.34 (m, 1H), 3.09 (m, 1H), 2.00 (m, 2H), 1.92 (m, 2H), 1.83 (m, 2H), 1.63 (m, 2H). ^13^C NMR (101 MHz, DMSO-*d*~6~) *δ* 176.13, 172.10, 158.21, 153.90, 153.74, 150.43, 145.65, 145.54, 134.37, 130.55, 126.02, 117.47, 115.26, 100.25, 67.53, 57.02, 53.05, 36.49, 32.20, 24.80. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~22~H~23~N~6~O~4~FS 487.1558, Found 487.1541.

### 4.7.2. 5-(4-(2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo\[3,4-d\]pyrimidin-6-yl)amino)ethoxy)-3-(trifluoromethyl)benzyl)thiazolidine-2,4-dione (**14b**) {#s0260}

White solid, Yield 35%; Purity: 98%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 12.04 (s, 1H), 10.64 (s, 1H), 7.75 (s, 1H), 7.49 (d, *J* = 9.1 Hz, 2H), 7.29 (d, *J* = 8.3 Hz, 1H), 6.58 (m, 1H), 4.93 (m, 2H), 4.27 (t, *J* = 5.3 Hz, 2H), 3.73 (dd, *J* = 10.6, 5.1 Hz, 2H), 3.39 (m, 1H), 3.20 (m, 1H), 1.99 (m, 2H), 1.91 (m, 2H), 1.82 (m 2H), 1.62 (m, 2H). ^13^C NMR (101 MHz, DMSO-*d*~6~) *δ* 176.10, 171.99, 158.29, 155.68, 153.90, 153.79, 135.52, 134.30, 129.28, 128.21, 128.16, 117.23, 114.18, 100.26, 67.51, 57.07, 52.94, 36.13, 32.15, 24.78. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~23~H~23~N~6~O~4~F~3~S 537.1526, Found 537.1528.

### 4.7.3. 5-(4-(2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo\[3,4-d\]pyrimidin-6-yl)amino)ethoxy)-3-fluoro-5-methoxybenzyl)thiazolidine-2,4-dione (**14c**) {#s0265}

Light yellow solid, Yield 35%; Purity: 96%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 12.06 (s, 1H), 10.59 (s, 1H), 7.74 (s, 1H), 6.82 (s, 1H), 6.77 (dd, *J* = 11.1, 1.5 Hz, 1H), 6.63 (t, *J* = 5.4 Hz, 1H), 4.90 (m, 2H), 4.11 (t, *J* = 5.5 Hz, 2H), 3.78 (s, 3H), 3.61 (dd, *J* = 11.0, 5.5 Hz, 2H), 3.37 (m, 1H), 3.04 (m, 1H), 1.99 (m, 2H), 1.90 (m, 2H), 1.82 (m, 2H), 1.63 (m, 2H). ^13^C NMR (101 MHz, DMSO-*d*~6~) *δ* 176.31, 172.23, 158.27, 157.06, 156.86, 154.36, 153.93, 153.88, 153.73, 134.33, 115.27, 109.98, 109.46, 100.22, 72.07, 57.03, 56.67, 52.92, 37.58, 32.16, 24.79. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~23~H~25~N~6~O~5~FS 517.1664, Found 517.1652.

### 4.7.4. 5-(4-(2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo\[3,4-d\]pyrimidin-6-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione (**14d**) {#s0270}

White solid, Yield 64%; Purity: 95%; ^1^H NMR (400 MHz, MeOD) *δ* 7.81 (s, 1H), 7.18 (d, *J* = 8.4 Hz, 2H), 6.92 (d, *J* = 8.4 Hz, 2H), 5.04 (m, 1H), 4.66 (dd, *J* = 8.8, 4.0 Hz, 1H), 4.18 (t, *J* = 5.4 Hz, 2H), 3.81 (t, *J* = 5.4 Hz, 2H), 3.37 (dd, *J* = 14.2, 4.4 Hz, 1H), 3.09 (dd, *J* = 14.2, 7.0 Hz, 1H), 2.06 (m, 4H), 1.94 (dd, *J* = 9.1, 5.6 Hz, 2H), 1.72 (m, 2H).^13^C NMR (101 MHz, Acetone) *δ* 205.32, 205.26, 158.05, 153.32, 133.75, 130.55, 129.68, 129.06, 114.51, 100.23, 66.17, 57.03, 53.30, 40.27, 36.95, 31.82, 31.75, 26.89, 24.53, 22.45, 13.48. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~22~H~24~N~6~O~4~S 469.1653, Found 469.1652.

### 4.7.5. 5-(4-((S)-2-((1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo\[3,4-d\]pyrimidin-6-yl)amino)propoxy)benzyl)thiazolidine-2,4-dione (**15**) {#s0275}

White solid, Yield 71%; Purity: 95%; ^1^H NMR (400 MHz, DMSO-*d*~6~) *δ* 10.37 (s, 1H), 7.75 (s, 1H), 7.16 (d, *J* = 8.6 Hz, 2H), 6.95 (d, *J* = 8.6 Hz, 2H), 6.79 (s, 1H), 4.97--4.87 (m, 1H), 4.79 (dd, *J* = 9.0, 4.2 Hz, 1H), 4.39--4.29 (m, 1H), 4.10 (dd, *J* = 9.8, 4.7 Hz, 1H), 3.96 (dd, *J* = 9.7, 5.5 Hz, 1H), 3.03 (dd, *J* = 14.1, 9.1 Hz, 1H), 1.97 (ddd, *J* = 17.5, 9.5, 5.3 Hz, 4H), 1.88--1.80 (m, 2H), 1.69--1.61 (m, 2H), 1.29 (d, *J* = 6.7 Hz, 2H). ^13^C NMR (101 MHz, DMSO-*d*~6~) *δ* 158.11, 157.83, 153.94, 153.19, 134.33, 130.81, 129.74, 114.91, 100.25, 70.47, 57.16, 54.15, 45.91, 37.02, 32.20, 32.15, 24.81, 17.62. HR-MS (ESI-TOF) *m/z* \[M + H\]^+^ Calcd. for C~23~H~26~N~6~O~4~S 483.1809, Found 483.1807.

4.8. In vitro bioassay test for the inhibition of PDE9 {#s0280}
------------------------------------------------------

The PDE9A2 protein was purified by the protocols according to our previous reports[@bib24], [@bib33]. ^3^H-cGMP was the substrate for the biological test against PDE9A2. ^3^H-cGMP was diluted with the assay buffer, which contained 20−50 mmol/L Tris--HCl (pH 8.0), 10 mmol/L MgCl~2~, and 1 mmol/L DTT to 20,000--30,000 cpm per assay. The reaction was performed at 25 °C for 15 min and was terminated by the addition of 0.2 mol/L ZnSO~4~. After the addition of 0.1 mol/L Ba(OH)~2~, a precipitate was formed, and the unreacted ^3^H-cGMP was left in the supernatant. The radioactivity in the supernatant was measured in 2.5 mL of Ultima Gold liquid scintillation cocktail (PerkinElmer) using a PerkinElmer 2910 liquid scintillation counter. For the measurement of IC~50~ of inhibitors, eight different concentrations were used, and each measurement was repeated three times. The IC~50~ values against PDE9 were calculated by nonlinear regression. The mean values of the measurements were considered as the final IC~50~ values with the SD values of the measurements.

4.9. In vitro assay for inhibition of the lead compounds on PDE1B, PDE4D, PDE7A and PDE8A {#s0285}
-----------------------------------------------------------------------------------------

The catalytic domains of PDE1B (10-487), PDE2A (580-919), PDE4D (86-413), PDE7A (130-482) and PDE8A (480-820) were purified with the published protocol[@bib37], [@bib38], [@bib39], [@bib40], [@bib41]. The enzymatic activities of PDE1B and PDE8A were assayed by using ^3^H-cGMP and ^3^H-cAMP as the substrates respectively, following the same procedure for PDE9A.

4.10. In vitro cell viability assay {#s0290}
-----------------------------------

SH-SY5Y cells were used for the cytotoxicity test by using the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2*H*-tetrazolium bromide) method[@bib42]. The SH-SY5Y cells (5 × 10^3^) were inoculated into a 96-well plate. After 24 h, compoundsat concentrations of 10, 20, 40, 60, 80 and 100 μmol/L, were added. After incubation for 48 h, MTT solution was added to each cell well and incubated for 4 h at 37 °C. After the purpleformazan dye was dissolved, 100 μL of DMSO was added to the cells. The absorbance of each cell well was measured at 570 nm using FlexStation 3 (Molecular Devices).

4.11. Molecular docking and MD simulations for PDE9A {#s0295}
----------------------------------------------------

The X-ray crystal structure of **28s**-PDE9A complex (PDB ID: 4GH6) reported in our previous studies^25^ was selected for molecular modeling, and Surflex-dock[@bib26] embedded in the software Tripos Sybyl 2.0 was used. Two metal ions crucial for the PDE\'s catalytic activity in the catalytic domain and water molecules coordinate these two metal ions were retained. Hydrogen atoms were added, and the ionizable residues were protonated at the neutral pH. The protomol, was generated using the parameters by default. The parameters of proto_thresh and proto_bloat were assigned 0.5 and 0, respectively. After the protomol was the prepared, molecular docking was performed for test molecules.

After molecular docking completed, similar MD simulation procedures as previous studies[@bib33] were used to equilibrate the whole system. Here 8 ns MD simulations were carried out in the NPT ensemble with a constant pressure of 1 atm and a constant temperature of 300 K. The periodic boundary conditions were adopted, along with an 8 Å cutoff for long-range electrostatic interactions with the partial mesh Ewald (PME) method[@bib43], [@bib44]. The SHAKE algorithm[@bib45], [@bib46] was utilized to deal with all bonds involving hydrogen atoms, and hence the time step was set to 2 fs. An Intel Xeon E5620 CPU and an NVIDIA Tesla C2050 GPU, which are available in performing floating-point calculations, were applied to accelerate the process of MD simulations for each system. Subsequently, the 100 snapshots were isolated from the final 1.0 ns period of the MD simulation trajectories, and then used for binding-free-energy calculations by the MM-PBSA approach[@bib34], [@bib35], [@bib36], [@bib47]. For the electrostatic contribution to the solvation-free energy, the PBSA program in the Amber 16[@bib48] suite was used, which could numerically solves the Poissone Boltzmann Eqs.

In light of the MM-PBSA method, the binding free energy (Δ*G*~bind~) can be calculated by the following Eq. [(1)](#eq0005){ref-type="disp-formula"}, where *G*~complex~, *G*~rec~ and *G*~lig~ represent the free energies of complex, receptor and ligand, respectively.$$\Delta G_{bind} = G_{complex} - G_{rec} - G_{lig}$$

Each free energy was evaluated as the sum of the MM energy *E*~MM~, the solvation free energy *G*~solv~, and the entropy contribution *S*, respectively, leading to Eq. [(2)](#eq0010){ref-type="disp-formula"}.$$\Delta G_{bind} = \Delta E_{MM} + \Delta G_{solv} - T\Delta S$$

Δ*E*~MM~ is the gas phase interaction energy, which can be decomposed into *E*~MM,comp~, *E*~MM,rec~ and *E*~MM,lig~. Solvation free energy is evaluated by the sum of the electrostatic solvation free energy (Δ*G*~PB~) and nonpolar solvation free energy (Δ*G*~np~), leading to Eq. [(3)](#eq0015){ref-type="disp-formula"}.$$\Delta G_{solv} = \Delta G_{PB} + \Delta G_{np}$$

Δ*G*~PB~ was calculated by the Poisson Boltzmann (PB) Eq, whereas Δ*G*~np~ was determined by use of Eq. [(4)](#eq0020){ref-type="disp-formula"}. The default parameters were adopted, with *γ* = 0.0072 kcal/(Å^2^) and *b* = 0 kcal/mol.$$\Delta G_{np} = \gamma SASA + b$$

In order to get the compromise between efficiency and accuracy, entropy contribution term (−*T*Δ*S*) was omitted for Δ*G*~bind~ in Eq. [(2)](#eq0010){ref-type="disp-formula"}, since the calculations of the entropy contribution is extremely time-consuming for large protein-ligand systems.
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[^1]: These authors made equal contribution to this work.

[^2]: \- not applicable.

[^3]: ^a^The IC~50~ value of the reference compound Bay-73-6691 was 48 nmol/L in the current study.

[^4]: ^b^IC~50~ values are given as the mean of three independent determinations.

[^5]: ^c^IC~50~ values reported in our previous literature[@bib23].

[^6]: ^d^The inhibition ratio of rosiglitazone against PDE9A at the concentration of 5 mmol/L.

[^7]: \- not applicable.

[^8]: Electrostatic interactions calculated by using the MM force field.

[^9]: van der Waals\' contributions from MM.

[^10]: Nonpolar contribution to solvation.

[^11]: Polar contribution to solvation.

[^12]: Δ*G*~bind,pred~ = Δ*G*~ele~ + Δ*G*~vdw~ + Δ*G*~nonpol,sol~ + Δ*G*~ele,sol~, predicted binding free energies in the absence of entropic contribution.
